Company Overview
Oisin Biotechnologies is a biotechnology firm devoted to the advancement of genetic medicines aimed at age-related diseases. Established in 2016, and based in Seattle, WA, Oisin focuses on therapies that enhance muscle growth, target senescent cells, and diminish unwanted fat cells. Their groundbreaking Fusogenix™ Proteo-Lipid Vehicle (PLV) technology allows for extensive biodistribution beyond the liver and enables repeated DNA and RNA payload dosing. Further information is available at [oisinbio.com](https://www.oisinbio.com/).
Financial Snapshot and Funding
Oisin Biotechnologies has amassed funding of approximately $27.5 million across multiple investment rounds, including contributions from prominent investors such as AbbVie Ventures, Methuselah Foundation, and VitaDAO. A notable milestone is the commencement of a $15 million Series A financing round in July 2024, aimed at propelling their therapeutic pipeline towards clinical trials.
- Annual Revenue: Approximately $1.6 million.
- Total Funding: $7.1 million
- Employee Count: 20, with a recent reduction in growth rate of -9%.
Leadership Team
- Matthew Scholz, Chief Executive Officer: Founder of Oisin Biotechnologies and its spin-out, OncoSenX, Scholz plays a pivotal role in advancing the company's mission to distribute innovative health solutions.
- John Lewis, Ph.D., Chief Science Officer: Co-founder committed to furthering Oisin's scientific endeavors with a background in biotechnology and translational oncology.
- Eric Garcia, Chief Operating Officer: Key figure in managing operational and business functions to ensure strategy execution.
- Stephen Hilbert, Chief Business Officer: Oversees commercial efforts, leveraging his experience in biotechnology, finance, and investment banking to enhance market presence.
- Kevin Perrott, Co-Founder and Scientific Advisor
- Hank Garcia, Lead Scientist
- Gary Hudson, Executive Chairman and Co-Founder
Recent Developments
In December 2024, Oisin was awarded a Methuselah Grant to support fat reduction studies and was recognized in 2020 by MIT Technology Review's "TR10" List for its contributions to innovative technologies. Their development in genetic medicines shows promise for significant impact within the longevity therapeutics landscape.
Competitor Analysis
Oisin Biotechnologies operates amid competitive pressure from other biotech companies pursuing anti-aging therapies. They aim to differentiate with DNA-targeted therapies, while rivals are exploring related areas like oncology and genetic disorders.
Top Competitors
1. Rooted Leaf Agritech
- Annual Revenue: $0.9M
- Employees: 6
2. Cerevast Medical
- Annual Revenue: $6M
- Employees: 5
3. Confidence Analytics
- Annual Revenue: $5.1M
- Employees: 33
4. Numa Bioscience
- Annual Revenue: $5.7M
- Employees: 37
Notable Industry and Key Players
- Alnylam Pharmaceuticals: Leader in RNA interference therapeutics.
- OncoSenX: Specialized in gene therapies targeting solid tumors.
Strategic Insights
Oisin Biotechnologies' approach distinguishes itself through precision in DNA-targeted therapies and may benefit from assessing potential collaborations and partnerships. While the company is small, its agility can be an advantage in innovation but may pose challenges in resource competition against larger firms like Alnylam Pharmaceuticals.
